Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research report report published on Sunday. The firm issued a hold rating on the biotechnology company’s stock. Separately, Maxim Group cut Brainstorm Cell Therapeutics from a buy rating to a hold rating in a research report on Thursday, September 28th. […]